Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Price Target at $973.13

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been given an average rating of “Moderate Buy” by the twenty-five brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $973.13.

A number of equities research analysts have commented on REGN shares. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Sanford C. Bernstein cut their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Finally, Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $665.46 on Friday. Regeneron Pharmaceuticals has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $73.13 billion, a P/E ratio of 17.38, a P/E/G ratio of 2.38 and a beta of 0.08. The stock’s fifty day moving average is $714.37 and its two-hundred day moving average is $906.38.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the business earned $11.86 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Signature Estate & Investment Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 9.7% in the 4th quarter. Signature Estate & Investment Advisors LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 29 shares during the period. Ashton Thomas Securities LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.5% in the 4th quarter. Ashton Thomas Securities LLC now owns 810 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 20 shares during the period. TD Asset Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 8.9% in the 4th quarter. TD Asset Management Inc. now owns 359,389 shares of the biopharmaceutical company’s stock valued at $256,004,000 after purchasing an additional 29,322 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $330,000. Finally, Dillon & Associates Inc. boosted its position in shares of Regeneron Pharmaceuticals by 2.8% in the 4th quarter. Dillon & Associates Inc. now owns 13,899 shares of the biopharmaceutical company’s stock valued at $9,896,000 after purchasing an additional 374 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.